Literature DB >> 25299236

Viral hepatitis among drug users in methadone maintenance: associated factors, vaccination outcomes, and interventions.

David C Perlman1, Ashly E Jordan, Courtney McKnight, Christopher Young, Kevin L Delucchi, James L Sorensen, Don C Des Jarlais, Carmen L Masson.   

Abstract

Drug users are at high risk of viral Hepatitis A, B, and C. The prevalence of Hepatitis A, Hepatitis B, and Hepatitis C, associated factors, and vaccine seroconversion among drug treatment program participants in a randomized controlled trial of hepatitis care coordination were examined. Of 489 participants, 44 and 47% required Hepatitis A/Hepatitis B vaccinations, respectively; 59% were Hepatitis C positive requiring linkage to care. Factors associated with serologic statuses, and vaccine seroconversion are reported; implications for strategies in drug treatment settings are discussed. Results suggest generalizable strategies for drug treatment programs to expand viral hepatitis screening, prevention, vaccination, and linkage to care.

Entities:  

Keywords:  Hepatitis C; Viral hepatitis; methadone maintenance treatment program; vaccination

Mesh:

Substances:

Year:  2014        PMID: 25299236      PMCID: PMC4275379          DOI: 10.1080/10550887.2014.969623

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  41 in total

Review 1.  Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment.

Authors:  Enrique R Pouget; Holly Hagan; Don C Des Jarlais
Journal:  Addiction       Date:  2012-04-17       Impact factor: 6.526

2.  Gaps in the drug-free and methadone treatment program response to Hepatitis C.

Authors:  Shiela M Strauss; Janetta Astone; Zdravko P Vassilev; Don C Des Jarlais; Holly Hagan
Journal:  J Subst Abuse Treat       Date:  2003-06

Review 3.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

Review 4.  Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.

Authors:  Ava John-Baptiste; Man Wah Yeung; Victoria Leung; Gabrielle van der Velde; Murray Krahn
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

5.  Changes in testing for human immunodeficiency virus, sexually transmitted infections, and hepatitis C virus in opioid treatment programs.

Authors:  Marcus A Bachhuber; Chinazo O Cunningham
Journal:  JAMA       Date:  2013-12-25       Impact factor: 56.272

6.  Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B.

Authors:  Gavin Bart; Paola Piccolo; Linqi Zhang; Ira Jacobson; Robert A Schaefer; Mary Jeanne Kreek
Journal:  Addiction       Date:  2008-04       Impact factor: 6.526

7.  Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial.

Authors:  Tim Weaver; Nicola Metrebian; Jennifer Hellier; Stephen Pilling; Vikki Charles; Nicholas Little; Dilkushi Poovendran; Luke Mitcheson; Frank Ryan; Owen Bowden-Jones; John Dunn; Anthony Glasper; Emily Finch; John Strang
Journal:  Lancet       Date:  2014-04-08       Impact factor: 79.321

8.  Causes of death and characteristics of decedents with viral hepatitis, United States, 2010.

Authors:  Kathleen N Ly; Jian Xing; R Monina Klevens; Ruth B Jiles; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079

Review 9.  Hepatitis C virus therapy update 2013.

Authors:  Lisa C Casey; William M Lee
Journal:  Curr Opin Gastroenterol       Date:  2013-05       Impact factor: 3.287

10.  Causes of death in patients with hepatitis B: a natural history cohort study in the United States.

Authors:  Jean-Luc Szpakowski; Lue-Yen Tucker
Journal:  Hepatology       Date:  2012-12-12       Impact factor: 17.425

View more
  5 in total

1.  An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.

Authors:  David C Perlman; Ashly E Jordan; Anneli Uuskula; Duong Thi Huong; Carmen L Masson; Bruce R Schackman; Don C Des Jarlais
Journal:  Int J Drug Policy       Date:  2015-04-27

2.  Longitudinal analysis of pain and illicit drug use behaviors in outpatients on methadone maintenance.

Authors:  Lara Dhingra; David C Perlman; Carmen Masson; Jack Chen; Courtney McKnight; Ashly E Jordan; Thomas Wasser; Russell K Portenoy; Martin D Cheatle
Journal:  Drug Alcohol Depend       Date:  2015-02-17       Impact factor: 4.492

3.  Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019.

Authors:  Shelley N Facente; Rachel Grinstein; Roberta Bruhn; Zhanna Kaidarova; Erin Wilson; Jennifer Hecht; Katie Burk; Eduard Grebe; Meghan D Morris
Journal:  PLoS One       Date:  2022-05-11       Impact factor: 3.752

4.  Gender disparity and temporal trend of liver cancer in China from 1990 to 2019 and predictions in a 25-year period.

Authors:  Tingting Yue; Ming Xu; Ting Cai; Haizhen Zhu; Mahmoud Reza Pourkarim; Erik De Clercq; Guangdi Li
Journal:  Front Public Health       Date:  2022-08-26

5.  Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.

Authors:  Shelley N Facente; Eduard Grebe; Katie Burk; Meghan D Morris; Edward L Murphy; Ali Mirzazadeh; Aaron A Smith; Melissa A Sanchez; Jennifer L Evans; Amy Nishimura; Henry F Raymond
Journal:  PLoS One       Date:  2018-04-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.